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ABSTRACT. Chicken IgY antibody has been extensively reported for various applications as an alternative to mam-
malian IgG. To evaluated the pharmacokinetics profile of chicken IgY in comparison with horse IgG. Chicken IgY an-
tibody was prepared by immunizing the white leghorn chicken with tetanus toxoid (TT) and then extracted anti-TT-IgY 
from immune egg yolks by PEG-6000 extraction. The titer of anti-TT-IgY was determined by ELISA in order to select 
the hyper immune eggs for further extraction. Rabbits were injected with 300 μg/kg of Chicken IgY and horse IgG by 
intravenous (i.v.) and intramuscular (i.m.) administrations. Then, the concentrations of IgY and IgG in rabbit serum were 
determined using indirect ELISA. Pharmacokinetic parameters were estimated using non-compartmental analysis. IgY 
can reach higher concentration (Cmax= 4.54 mg/L after i.m. injection) within shorter time (Tmax= 0.12 h after i.m. injection) 
than IgG (Cmax= 3.99 ng/mL after i.m. injection; Tmax=0.11 h after i.m. injection), while the IgY lifespan (T1/2=26.98 h and 
31.98 h after i.v. and i.m. administration, respectively) in the body was comparable with IgG (T1/2=27.94 h and 29.58 h 
after i.v. and i.m. administration, respectively). IgY might be a promising choice as an alternative to mammalian sourced 
antibodies.
Keywords: tetanus, IgY, IgG, pharmacokinetics; intravenous administrations; intramuscular administrations
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INTRODUCTION 
Tetanus, known as lockjaw, is a fearful health problem in both human and animals caused by 
neurotoxin produced by the anaerobic bacterium 
clostridium tetanus, usually through contaminated 
wounds and will affect body’s muscles and nerves 
(Hertz and Sørensen, 2014). Prevention by appropri-
ate wound care (cleaning and antibiotics) and immu-
nization are vital. At present, tetanus can be prevented 
by the administration of tetanus toxoid, which induces 
specific antitoxins. In addition, antibody used for the 
prevention and treatment of tetanus dates from 1890, 
tetanus antitoxin is an important drug prevention and 
treatment of tetanus, such as tetanus antiserum (TAT) 
were obtained from tetanus toxoid immunized horse 
(Keller and Stiehm, 2000). TAT in an effort to toxin 
neutralization is a crucial part of the treatment, while 
its obviously adverse reactions (the high incidence of 
anaphylaxis) limited the clinical application (Shen 
and Zhang, 2012). And its preparation went against 
the animal welfare and required high production costs, 
which can in turn hamper its use (Luo, 2002). 
It has been reported very long ago, that egg yolk 
extracts laid by hens hyper immunized against teta-
nus toxin were capable of protecting mice from the 
toxin effect (Klemperer, 1893). However, antitoxin or 
antivenoms are mostly produced in hyper immunized 
mammals (Theakston and Warrell, 1991). Recently, 
numerous studies are supporting the immunothera-
peutic use of avian IgY antibodies (Diaz et al., 2014).
IgY is the functional equivalent of IgG in birds, 
reptiles and amphibian. It has gained significant at-
tention because of several attractive advantages than 
mammalian IgG including low-cost, easiness and high 
yield (Schade et al., 2005; Sun et al., 2013). Besides 
this, IgY has high affinity and does not react with Fc 
receptors and thereby possess low risk of adverse re-
actions in immunotherapeutic applications (Vázquez 
et al., 2010). However, the information on clinical 
success for IgY usage has not explored well to draw 
strong conclusions. Notably, the investigations on the 
applications of IgY to control non-enteric diseases; 
especially for intravenous administration (i.v.) are 
scanty. Only limited numbers of studies (with pre-
liminary findings) have been reported on IgY against 
snake venoms and some other toxins (Polson et al., 
1980; Diaz et al., 2014). Thus, it is indispensable to 
understand the consequences after i.v. or i.m. admin-
istration of IgY. Because, the effect of IgY therapy is 
mainly associated with knowledge about IgY pharma-
cokinetics (PK). The previous study have investigated 
the pharmacokinetics of antivenoms IgY in rabbits after 
i.v. administration, IgY PK lacks the fast initial decay, 
last less time in the body, reaches a smaller volume of 
distribution in steady state (Diaz et al., 2014). However, 
it would be still interesting to compare the pharmaco-
kinetic characteristics of IgY and IgG, and to evaluate 
the feasibility of IgY in parenteral administration with 
regard to its pharmacokinetic and safety concerns. 
MATERIALS & METHODS
2.1. Experimental animals and sampling procedures
White Leghorn chickens (25-week old ~ 2 kg of 
body weight) were purchased from local farm and 
adult New Zealand rabbits (18-week old ~ 3.0 ± 0.25 
kg of body weight) were procured from the Fourth 
Military Medical University (Xi’an, China). Hens and 
rabbits were kept in individual cages with food and 
water ad libitum. All experimental procedures in this 
study were carried out in accordance with university 
guidelines for care and use of laboratory animals. Pu-
rified anti-tetanus horse IgG was kindly provided by 
the Chifeng Boen pharmaceutical Ltd. Co. (Chifeng, 
Inner Mongolia, China). 
Rabbits were randomly divided into four groups 
(N=4) with six animals in each (n=6): IgY i.v. group; 
IgY i.m. group; IgG i.v.; and IgG i.m. group. The ex-
perimental was conducted as the method previously 
described by Díaz et al (Sun et al., 2013). Briefly, ex-
perimental animals were immobilized with a harness, 
and catheterized in the right ear marginal vein with a 
retention needle. After injection of IgY or IgG (300 
μg/kg), the opposite side vastus muscle or the margin-
al vein from the opposite side ear was used to draw 
blood samples. A blank sample was drawn from the 
catheterized ear at t=0. Blood samples (400 μL) were 
drawn at 2 min intervals from 0 to 20 min, then at 10 
min intervals up to 60 min, then at 3 h intervals for up 
to 12 h, then at 24 h and at days 3, 5, 7, 9, 11 and 15. 
Blood samples were incubated for 1 h at 37 °C and 
centrifuged for 10 min at 5000 g at 4 °C. Serum was 
separated and kept frozen at -20 °C until used.
2.2. Preparation and characterization of specific IgY
Inactivated tetanus toxoid 500 μL (1300 UI/mL) 
mixed with Freund’s complete adjuvant (FCA; Sig-
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ma) was intramuscularly injected to 25-week-old 
white Leghorn chickens at different sites of breast 
muscles. The booster injection with same dose of vac-
cine and Freund’s incomplete adjuvant (FIA; Sigma) 
was given at 21, 35, 49 and 63 days after the first im-
munization. Eggs were collected daily and stored at 
4 oC. IgY was extracted as per the method previously 
described by Polson et al (Zhang and Zheng, 2012). 
In brief, 3.5% (w/v) polyethylene glycol (PEG-6000) in 
PBS, 10 mM, pH 7.2) was added to yolk. After gentle 
shaking at room temperature for 10 min, mixture was 
subjected to centrifugation at 16,000 g for 20 min at 4 
oC. PEG-6000 was added to supernatant at a final con-
centration of 12% (w/v). After gentle shaking at room 
temperature for 10 min, the mixture was centrifuged as 
above. The pellet was dissolved in 10 mL of PBS and 
12% (w/v) PEG-6000 was added and again centrifuged 
as above. Finally, the pellet was dissolved in 1.2 mL of 
PBS and dialyzed against PBS for overnight at 4 oC. The 
purity of IgY was evaluated by SDS-PAGE and stored 
at -20 oC. The titer of specific IgY was determined as 
described in our previous report (He et al., 2014).
2.3. Determination of serum IgY and IgG concentrations
The standard IgY and IgG (Zen bioscience. 
Chengdu, China) were serially diluted in sterile tubes 
using CBS. Microtiter plates were coated with differ-
ent dilutions of standard IgY (100 μg/mL, 10 μg/mL, 
1 μg/mL, 0.1 μg/mL, 0.01 μg/mL) and IgG (100 μg/
mL, 50 μg/mL, 10 μg/mL, 2 μg/mL, 1 μg/mL, 0.1 μg/
mL, 0.01 μg/mL) (Zen bioscience, Chengdu, China) 
separately and incubated overnight at 4 oC. After in-
cubation, the plates were washed 3 times with PBS 
containing 0.5% Tween-20 (PBST) and unbound 
sites were blocked with PBS containing 5% skim 
milk (PBSM) for 1 h at 37 oC. Subsequent washing 
with 0.5% PBST three times, HRP conjugated goat 
anti-chicken IgY (Abcam, Canada) or goat anti-horse 
IgG (Abcam, Canada) was added. Plates were incu-
bated for 1h at 37 °C. Finally, 100μL TMB was added 
to each well as substrate and incubated for 15 min at 
room temperature, the reaction was stopped by adding 
50 μL of H2SO4 (2 mol/L). The OD450 was measured 
on a micro plate reader. Standard curves were plotted 
to determine IgY and IgG concentration. Rabbit serum 
samples were diluted to 5-fold with CBS and coated to 
microplates at 4oC overnight (triplicates). The remain-
ing steps were performed as described above.
2.4. Determination of rabbit IgG titer against chick-
en IgY and horse IgG
The titer of rabbit anti-IgY and anti-IgG antibod-
ies were measured using indirect ELISA. Briefly, the 
IgY and IgG were coated to plates overnight at 4 °C. 
After three times with PBST, unbound sites were 
blocked with 5% PBSM and incubated for 2 h at 37 
°C. After washing three times with PBST, rabbit se-
rum was added to each well and incubated for 2 h at 37 
°C. After washing with PBST, HRP-conjugated goat 
anti-rabbit antibody (Abcam, UK) (100 μL/well) was 
added to plates for 1 h at 37 °C. After washing, the 
remaining steps were performed as described above.
2.5. Pharmacokinetics analysis
The measured plasma concentration data were 
processed using software DAS 2.0 (Mathematical 
Pharmacology Professional Committee of China, 
Shanghai, China) as previous description (Huang et 
al., 2014), calculating pharmacokinetic parameters 
for each group. Pharmacokinetic parameters were es-
timated using non-compartmental analysis. All data 
were presented as the Mean ± Standard deviation.
Pharmacokinetic abbreviations: AUC (0-∞), area 
under the plasma concentration-time curve at time 
= ∞; AUMC (0-∞), area under the first moment of the 
concentration-time curve at time = ∞; CLz, total body 
clearance; T1/2z, biological half time; MRT (0-∞), mean 
residence time at time = ∞; Cmax, maximum concentra-
tion; Tmax, time to reach the maximum concentration; 
Vz, volume of blood.
2.6. Pharmacokinetic appendix
2.6.1. Non multi-exponential pharmacokinetics 
analysis
Since the concentration vs time curves deviated 
markedly from a tri-exponential model, pharmaco-
kinetics parameters were calculated from AUC and 
AUMC values obtained by trapezoidal numerical inte-
gration of the curves (Vázquez et al., 2010).
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Where n is the number sampled points, and  is the time at which was sampled. Likewise, 
If tn is long enough to be taken as a good approx-
imation to infinity, Eqs. (1) and (2) reduce to just the 
sum terms between brackets. Since in our case the con-
centration vs time curves for IgY were towards zero 
after 216 h at the end of the observation period, Cn was 
taken as 0 or, equivalently, λz=tz-1 was taken as infinity.
2.6.2. Determining pharmacokinetics parameters
The expressions to calculate pharmacokinetics pa-
rameters were described in Table 1 and summarized 
here. CLz, Vz and T1/2z are statistical parameters. They 
calculated with the following formula (Zhang and 
Zheng, 2012).
The half-lives of distribution and elimination were 
given by the expression:
Where, C means the dose of the drug. 
The apparent volume of distribution (Vz) was cal-
culated using the equations:
Figure 1. SDS-PAGE analysis of IgY extract.
Note: Lane M: molecular weight marker; Lane 1: IgY isolated 
by PEG-6000.
Where, Ke is the elimination rate constant.
The total body clearance (CLz) was given by the 
equation:
MRT is the mean residence time or average time a 
molecule staying in the body and calculated using the 
following equation: 
RESULTS
3.1. Preparation of anti-tetanus IgY antibody and 
evaluation of IgY titer
The purity assessment of IgY extract by SDS-
PAGE showed two protein bands i.e., a heavy chain 
(66 kDa) and a light chain (27 kDa) (Fig. 1). Indirect 
ELISA was used to monitor the titer of specific IgY 
against tetanus toxoid. After third immunization, the 
titer of anti-tetanus IgY was increased up to 1:68,000 
and remained stable for one month.
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Figure 2. Standard curves of 
IgY and IgG.
Note: A represents the standard 
curve of IgY; B represents the 
standard curve of IgG.
Figure 3. Plasma of IgY and 
IgG concent ra t ions- t ime 
profiles in rabbit following 
single IV and IM injection at a 
dosage of 300µg/kg BW (n=6).
Note: A, B presents the con-
centration-time (0 to 1 h and 0 
to 168 h) of IgY after IV and 
IM injections, respectively; 
C, D presents the concentra-
tion-time (0 to 1 h and 0 to 
168 h) of IgG after IV and IM 
injections, respectively.
3.2. Development of standard curve for IgY and IgG
A series of OD450 values were obtained from ELISA. OriginPro.8 was used to plot the standard curve (Fig. 
2). The values showed an excellent linear relation y = 0.4623x + 1.0317 (R2 = 0.9951) for IgY and y = 0.2527x 
+ 0.9387 (R2 = 0.9945) for IgG.
3.3. Concentration-time profiles of IgY and IgG in rabbit serum
The concentrations of IgY and IgG in rabbit were determined by ELISA for over a period of time. It is a semi 
logarithmic plot of serum [IgY] and [IgG] vs time elapsed after i.v. and i.m. administration (Fig. 3). Their levels 
were undetectable until 216 h.
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Table 1. Pharmacokinetic parameters of IgY and IgG in Rabbit (n=6).
Parameter IV IgY IV IgG IM IgY IM IgG 
Dose (μg kg-1) 300 300 300 300
Tmax (h) -- -- 0.12±0.03 0.11 ±0.07
Cmax (mg L
-1) -- -- 4.54±0.33 3.99±0.31
T1/2z (h) 26.98±4.35 27.94±4.31 31.98±4.22 29.58±1.48
AUC(0-∞) (mg h L
-1) 132.87±17.66 139.10±32.00 112.94±26.98 160.63±15.25
AUMC(0-∞) (mg h
2 L-1) 4921.33±956.87 5821.55±810.92 4435.56±1113.91 6770.89±637.99
MRT(0-∞) (h) 36.85±4.05 42.7±4.98 39.53±3.84 42.33±4.27
CLz (mL h
-1 kg-1) 2.00±0.00 2.00±1.00 3.00±1.11 2.00±0.00
Vz (L kg
-1) 0.09±0.02 0.09±0.02 0.13±0.06 0.08±0.01
(Notes: AUC(0-∞), area under the plasma concentration-time curve at time = ∞; AUMC(0-∞), area under the first moment of the concentra-
tion-time curve at time = ∞; CLz, total body clearance; T1/2z, biological half-time; MRT(0-∞), mean residence time at time = ∞; Cmax, maxi-
mum observed plasma IgY concentration; Tmax, time to reach the maximum concentration; Vz, volume of blood; BW, rabbit body weight. 
Data presented as medians and their 95% confidence intervals (between parentheses) calculated for 6 rabbits.)
Figure 4. Titers of anti-IgY and anti-
IgG antibody in rabbit serum.
Note: A and B present titers of an-
ti-IgY body in rabbit serum following 
IV and IM injection, respectively; C 
and D present titers of anti-IgG body 
in rabbit serum following IV and IM 
injection, respectively.
3.4. Pharmacokinetic characteristics of IgY and IgG
The main pharmacokinetic parameters were summarized in Table 1. The rabbits were carefully observed 
during and after the experimental period, and there was no observable adverse reaction in terms of animal behav-
ior, including appetite, hair, spirits atrophy, allergy, stress and death. 
3.5. Titers of rabbit anti-IgY and anti-IgG antibody
After receiving IgY and IgG, anti-IgY and anti-IgG titers were monitored in rabbits (Fig. 4). After i.v. 72 
h, titers of anti-chicken and anti-horse IgG reached 1:1000 and 1:200; and attained the peak 1:3200 for IgY and 
1:2000 for IgG after 300 h. In i.m. group, titer of anti-IgY was 1:500 and 1:200 for anti-IgG at 72 h. After 300 h, 
titer was (1:3200) for IgY and (1:1000) for IgG. 
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DISCUSSION
IgY has been clinically used as an effective tool 
for the treatment and control of various infections es-
pecially in veterinary medicine (Spillner et al., 2012; 
Zolfagharian and Dounighi, 2015). Even though, the 
IgY has been considered as an promising alternative to 
conventional IgG to some extent, the pharmacokinetics 
behavior and safety are not well explored in mammals. 
Hence, we had designed this study to evaluate the IgY 
pharmacokinetics profile after i.v. and i.m. administra-
tions in parallel to IgG targeted against the same anti-
gen. In this study, the tetanus toxoid has been used just 
as a tool, the exact focus of the study was to explore 
the general bodily effect on IgY (regardless of antigen 
specificity) as well as IgG administration (for compar-
ison) in order to appraise the IgY for non-enteric pas-
sive immunization. However, it is interesting to men-
tion that, more than 100 years ago the first investigated 
IgG as well as IgY both were targeting tetanus toxin 
(Behring and Kitasato, 1890; Klemperer, 1893); even, 
the anti-tetanus serum is still under use. The previous 
reports by Klemperer in 1893 and Guimarães et al., in 
2009 have stated that, IgY treatment could reduce the 
risk of tetanus toxin (Klemperer, 1893; Guimarães et 
al., 2009), we also experienced similar neutralization 
effects of IgY (data not shown). As far as antivenoms 
produced based on chicken IgY have been tried in hu-
mans (Kiem, 2000; Diaz et al., 2014).
Different research groups have reported on IgY 
pharmacodynamics (PD) profile. Notably, anti-venom 
IgY generated in chicken was studied to evaluate ven-
om neutralizing potential. Neutralizing potency of IgY 
anti-B. arietans was particularly efficient, as shown by 
the capacity of 1440 mg IgY to neutralize 62.2 LD50 
of the venom (de Almeida et al., 2008). Another re-
port stated that, the LD50 of venom for 18 g of mice 
was found to be 10 mg for Cobra and 3 mg for Krait 
venoms. The median effective dose (ED50) of anti-Co-
bra venom was 4.48 mg/5 LD50 and 1.0 ml neutral-
ized 0.127 mg of Cobra venom and the median ED50 
of anti-Krait venom was 3.18 mg/5 LD50 and 1.0 mL 
neutralized 0.051 mg of Krait venom (Meenatchisund-
aram et al., 2008). In neutralization study, a preincu-
bated mixture of both affinity-purified (50mg/kg body 
weight) as well as partially purified (210 mg/kg body 
weight) anti-Echis carinatus IgY with 2 LD50 dose of 
E. carinatus venom (2×6.65 mg/kg body weight) gave 
100% protection in mice when administered subcuta-
neously (Paul et al., 2007). Even IgY was capable of 
neutralizing lethal toxic activity of the pool of Both-
rops sp venoms from five species, with an ED50 of 365 
mL/2 LD50 and, 1.0 mL of IgY antivenom neutralized 
0.154 mg of venom (Araujo et al., 2010). Indeed, an-
ti-venom IgY can provide a higher bioactivity than an-
tidotes raised in horses (Thalley and Carroll, 1990). In 
addition, IgY could protect donkeys from 1 minimum 
lethal dose (MLD) of Clostridium tetanic through pas-
sive immunization before and after infection (Meshad 
et al., 2013). Furthermore, IgY has equally efficacy to 
IgG in prophylaxis and treatment of tetanus in mice. In 
a previous study showed that 1000 units was the best 
therapeutic dose (Smith and MacIver, 1969).
In the present study, during both i.v. and i.m. ad-
ministrations, the AUC for IgY was comparable (in 
i.v.) or lower (in i.m.) than that of IgG. This slight 
variation was probably impacted by the faster elimi-
nation of IgY in rabbit and/or related with the minor 
different in binding affinity between rabbit FcRn and 
horse IgG, which would have controlled the rapid deg-
radation of exogenous IgG. In contrast, the mammali-
an FcRn could not bind with avian IgY (Murai et al., 
2013), there is a clear phylogenetic distance between 
chicken and rabbit, compared with rabbit and horse; 
thus the rabbit’s immune response to the exogenous 
IgY was slightly higher than exogenous IgG, never-
theless they are still in a comparable level. However, 
IgY exhibited higher Cmax compared to IgG (i.m.) that 
is IgY can quickly reach a higher initial concentration 
than IgG; Thus, it can effectively act against the toxins 
injected into the body. It is necessary to admit that in 
our result, IgG i.v. administration in rabbit exhibited 
lower AUC than that of i.m. administration (Table 1), 
this could be experimental error caused by individual 
different of rabbits, and the possible cross reactivity 
of anti-horse secondary IgG to rabbit IgG could play 
a role. 
In summary, these findings suggest that, PK pro-
files between IgY and IgG are still comparable despite 
of some observable variations. Furthermore, the PK 
profile could diverse from species to species, as well 
as to pathological/physiological statuses; even in this 
study, the rabbits were not challenged with toxins. 
IgY has been considered as a promising choice for 
the enteric diseases notably in veterinary medicine; 
our observations suggest that, further investigations 
are indispensable to understand the IgY PK profile for 
non-enteric usage. 
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